Key facts
- Iota Biosciences’s last known valuation is $176.5M (Oct 2020).
- It has raised $15.6M across 1 recorded rounds; the latest was Early Stage VC ($15.0M) in May 2018.
- Notable investors include Dorm Room Fund.
- Iota Biosciences has filed 1 Form D with the SEC, most recently May 2018 ($15.0M sold to 17 investors).
- Status: Acquired/Merged (Operating Subsidiary).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Iota Biosciences
Funding rounds
1 roundsAbout Iota Biosciences
Developer of bioelectronics technology designed to facilitate completely wireless and untethered neural recordings in the brain. The company focuses on creating and develop state-of-the-art diagnostic and therapeutic bioelectronic devices that are safe and effective and its technology utilizes implantable, mote-sized, ultrasonic sensors to eliminate the need for wires that go through the skull and assists in untethered, real-time wireless cortical recording, enabling physicians to get an improved method of monitoring and treating diseases.
- Sector
- Healthcare
- HQ
- Alameda, CA, United States
- Founded
- 2017
- Employees
- 93
- Website
- iota.bio/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Iota Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Iota Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Iota Biosciences in its N-PORT filings yet. We sweep new filings monthly.